5 research outputs found
Peto Odds ratio of vandetanib-associated all grade (A) and high-grade (B) prolonged QTc interval versus control from the randomized controlled trials of patients with non-thyroid cancer.
<p>Peto Odds ratio of vandetanib-associated all grade (A) and high-grade (B) prolonged QTc interval versus control from the randomized controlled trials of patients with non-thyroid cancer.</p
Peto Odds ratio of vandetanib-associated all grade (A) and high-grade (B) prolonged QTc interval versus control from the randomized controlled trials of patients with thyroid cancer.
<p>Peto Odds ratio of vandetanib-associated all grade (A) and high-grade (B) prolonged QTc interval versus control from the randomized controlled trials of patients with thyroid cancer.</p
Characteristics of clinical trials and patients included in the meta-analysis.
<p>NSCLC:non-small-cell lung cancer; SCLC:small-cell lung cancer; PC:paclitaxel and carboplatin; MTC:medullary thyroid cancer; DTC:differentiated thyroid cancer.</p
Forest plot for meta-analysis of incidence of all grade (A) and high-grade (B) prolonged QTc interval in patients with non-thyroid cancer who were assigned vandetanib.
<p>Forest plot for meta-analysis of incidence of all grade (A) and high-grade (B) prolonged QTc interval in patients with non-thyroid cancer who were assigned vandetanib.</p